Biomerica Announces Real-World Results Showing Effectiveness Of inFoods IBS Product, Along With Launch Of Proprietary Real-Time Patient Feedback System To Enhance Symptom Tracking And Improve Patient Outcomes

• Real-World Impact: Initial data from over 360 patients shows inFoods® IBS delivered an average 48.5% reduction in gastrointestinal pain and a 49.8% reduction in bloating over an 8-week period
   
• First-of-Its-Kind inFoods® IBS Feedback Platform: New real-time feedback system empowers physicians to adjust patient treatment based on actionable, patient-reported outcomes
   
• Precision Medicine: inFoods® IBS identifies specific individual food triggers that can cause IBS symptoms (bloating, pain, diarrhea, and constipation) offering a personalized, non-drug solution

IRVINE, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), an innovator in diagnostic-guided therapy, today announced compelling real-world results demonstrating the effectiveness of its inFoods® IBS product, along with the launch of a proprietary real-time patient feedback system to enhance symptom tracking and improve patient outcomes.

The initial analysis from more than 360 patients who enrolled in the real world inFoods® IBS study revealed an average:

• 48.5% reduction in gastrointestinal (GI) pain
• 49.8% reduction in bloating

This ongoing study tracks symptom reduction from a two-week baseline through an eight-week intervention, during which patients eliminate specific trigger foods identified using the InFoods® IBS diagnostic system. These real-world outcomes align with—and in some cases exceed—results from prior randomized clinical trials conducted at leading U.S. medical centers.